Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder

医学 右美托咪定 安慰剂 麻醉 随机对照试验 临床终点 情感障碍症 双相情感障碍 安慰剂对照研究 内科学 双盲 镇静 病理 替代医学 狂躁 锂(药物)
作者
Sheldon Preskorn,Scott L. Zeller,Leslie Citrome,Jeffrey S. Finman,Joseph F. Goldberg,Maurizio Fava,Rishi Kakar,Michael De Vivo,Frank D. Yocca,Robert Risinger
出处
期刊:JAMA [American Medical Association]
卷期号:327 (8): 727-727 被引量:61
标识
DOI:10.1001/jama.2022.0799
摘要

Importance

Acute agitation is common in patients with bipolar disorder and requires urgent management to relieve distress and to prevent escalation to aggressive behavior.

Objective

To evaluate the effect of orally absorbed, sublingual dexmedetomidine, a selective α2A-adrenergic receptor agonist on symptoms of acute agitation in patients with bipolar disorder.

Design, Setting, and Participants

Phase 3, randomized, double-blind, placebo-controlled trial conducted in 15 sites in the US with enrollment between February 24, 2020, and April 27, 2020, and final follow-up on May 21, 2020. A total of 380 adults with bipolar I or II disorder were randomized and 362 completed the study.

Interventions

Participants were randomized to 3 groups: sublingual dexmedetomidine 180 μg (n = 127), sublingual dexmedetomidine 120 μg (n = 127), or placebo (n = 126).

Main Outcomes and Measures

The primary efficacy end point was the mean change from baseline at 2 hours for the Positive and Negative Syndrome Scale-Excited Component (PEC) total score. The range of possible total scores is 5 (absence of agitation) to 35 (extremely severe). The secondary end point was the earliest time of a statistically significant change in PEC total score from baseline for the drug vs placebo. On the primary efficacy end point, to account for multiplicity associated with comparing 2 sublingual dexmedetomidine doses with placebo, the 2-sided significance level for each dose vs placebo was set at .025.

Results

Of 380 patients randomized (mean age, 45.6 years; 54.8% women; and 56.1% Black individuals), 378 (99.5%) self-administered the study medication and completed the study. Baseline agitation was mild to moderate, with an overall mean PEC total score of 18.0. Two hours after taking the medication, the mean changes from baseline in PEC total score were −10.4 for sublingual dexmedetomidine 180 μg, −9.0 for sublingual dexmedetomidine 120 μg, and −4.9 for placebo. Least-square mean differences from placebo in the sublingual dexmedetomidine groups at 2 hours were −5.4 (97.5% CI, −6.6 to −4.2) for 180 μg and −4.1 (97.5% CI, −5.3 to −2.9) for 120 μg (both dosesP < .001 vs placebo). Treatment effects began 20 minutes after taking the medication among patients in the sublingual dexmedetomidine groups (least-square mean difference for 180 μg, −1.1 [97.5% CI, −2.0 to −0.2];P = .007; for 120 μg, −1.0 [97.5% CI, −1.9 to −0.1];P = .009). Adverse events occurred in 35.7% of patients taking 180 μg of dexmedetomidine, 34.9% taking 120 μg, and 17.5% taking placebo. The most common adverse events (≥5%) in the respective 180 μg, 120 μg, and placebo groups were somnolence (21.4% and 20.6% vs 4.8%); dry mouth (4.8% and 7.1% vs 0.8%); hypotension (6.3% and 4.8% vs 0%); and dizziness (5.6% and 5.6% vs 0.8%).

Conclusions and Relevance

Among patients with mild to moderate agitation associated with bipolar disorder, treatment with a sublingual film formulation of dexmedetomidine 120 μg or 180 μg, compared with placebo, resulted in significantly greater reduction in the agitation score at 2 hours. Further research is needed to understand the spectrum of patients for whom this treatment would be effective and feasible and to better understand the clinical importance of the observed effect size.

Trial Registration

ClinicalTrials.gov Identifier:NCT04276883
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐乐应助浮生采纳,获得10
1秒前
llz发布了新的文献求助10
1秒前
youwenjing11发布了新的文献求助10
1秒前
单薄的咖啡完成签到,获得积分10
1秒前
1秒前
dpp发布了新的文献求助10
3秒前
木木完成签到,获得积分10
3秒前
Clover完成签到 ,获得积分10
4秒前
4秒前
5秒前
5秒前
Hello应助youwenjing11采纳,获得10
5秒前
shengch0234完成签到,获得积分10
6秒前
6秒前
Hoooo...发布了新的文献求助10
6秒前
CDH发布了新的文献求助10
7秒前
酷波er应助正直的白开水采纳,获得10
7秒前
7秒前
dpp完成签到,获得积分20
7秒前
小二郎应助满眼星辰采纳,获得10
8秒前
阮绿凝发布了新的文献求助30
10秒前
10秒前
卡司完成签到,获得积分10
10秒前
chriswtr完成签到,获得积分10
12秒前
12秒前
13秒前
只A不B应助sinan采纳,获得30
13秒前
样杨羊发布了新的文献求助10
13秒前
谨慎老大完成签到,获得积分10
14秒前
15秒前
阮绿凝完成签到,获得积分10
15秒前
15秒前
16秒前
16秒前
ABC完成签到,获得积分10
16秒前
猪猪侠完成签到,获得积分10
17秒前
17秒前
王怜花发布了新的文献求助20
18秒前
谨慎老大发布了新的文献求助10
18秒前
19秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Conference Record, IAS Annual Meeting 1977 820
England and the Discovery of America, 1481-1620 600
Teaching language in context (Third edition) by Derewianka, Beverly; Jones, Pauline 550
Oligomycin, a new antifungal antibiotic 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3583562
求助须知:如何正确求助?哪些是违规求助? 3152720
关于积分的说明 9493986
捐赠科研通 2855337
什么是DOI,文献DOI怎么找? 1569506
邀请新用户注册赠送积分活动 735294
科研通“疑难数据库(出版商)”最低求助积分说明 721167